Wird geladen...
ENGAGE and EMERGE: Truth and consequences?
The potential benefit of the anti‐amyloid drug aducanumab based on results of recent EMERGE and ENGAGE clinical trials has generated great controversy and has very important implications for the future of anti‐amyloid drug therapies. The two trials of 18‐month duration were done in patients with mil...
Gespeichert in:
| Veröffentlicht in: | Alzheimers Dement |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley and Sons Inc.
2021
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8248059/ https://ncbi.nlm.nih.gov/pubmed/33656288 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/alz.12286 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|